Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia

Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia Acute promyelocytic leukemia (APL) is a molecularly well-defined disease, characterized by a specific chromosomal translocation; the improvement in biologic and clinical knowledge and subsequent introduction of molecularly targeted therapies have transformed the management of APL, with survival rates now exceeding 80%. Minimal residual disease (MRD) assessment in APL is the most important tool for its treatment; the prognostic role of the molecular detection of promyelocytic leukemia retinoic acid receptor α (PML-RARα) transcript after consolidation therapy in the early identification of the following hematologic relapse is now well established and guides preemptive therapy. First experiences performed with a qualitative polymerase chain reaction (PCR) approach were replaced with more accurate real-time quantitative PCR (RQ-PCR), which guarantees a numeric quantification of MRD. The identification of arsenic trioxide (ATO) as a valid therapy not only in relapsed patients but also as an alternative to standard therapy alone or in association with all-trans-retinoic acid enlarges the setting of validation of MRD evaluation in APL patients, considering a possible different clearance of PML-RARα with innovative therapy different from the standard ones. MRD monitoring demonstrated its validity also in the setting of relapsed patients with interesting results in the autologous and allogeneic stem cell transplantation setting or with the use of other biological agents. The aim of this review is to report and discuss the actual state of the art of MRD in APL. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia

Angelis, Federico; Breccia, Massimo
Oncology and Therapy , Volume 3 (2) – Oct 21, 2015
Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/molecular-monitoring-as-a-path-to-cure-acute-promyelocytic-leukemia-utfM64n0Lk
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-015-0013-8
Publisher site
See Article on Publisher Site

Abstract

Acute promyelocytic leukemia (APL) is a molecularly well-defined disease, characterized by a specific chromosomal translocation; the improvement in biologic and clinical knowledge and subsequent introduction of molecularly targeted therapies have transformed the management of APL, with survival rates now exceeding 80%. Minimal residual disease (MRD) assessment in APL is the most important tool for its treatment; the prognostic role of the molecular detection of promyelocytic leukemia retinoic acid receptor α (PML-RARα) transcript after consolidation therapy in the early identification of the following hematologic relapse is now well established and guides preemptive therapy. First experiences performed with a qualitative polymerase chain reaction (PCR) approach were replaced with more accurate real-time quantitative PCR (RQ-PCR), which guarantees a numeric quantification of MRD. The identification of arsenic trioxide (ATO) as a valid therapy not only in relapsed patients but also as an alternative to standard therapy alone or in association with all-trans-retinoic acid enlarges the setting of validation of MRD evaluation in APL patients, considering a possible different clearance of PML-RARα with innovative therapy different from the standard ones. MRD monitoring demonstrated its validity also in the setting of relapsed patients with interesting results in the autologous and allogeneic stem cell transplantation setting or with the use of other biological agents. The aim of this review is to report and discuss the actual state of the art of MRD in APL.

Journal

Oncology and Therapy – Springer Journals

Published: Oct 21, 2015

References

  • Expression pattern of the RARa-PML fusion gene in acute promyelocytic leukemia
    Alcalay, M; Zangrilli, D; Fagioli, M
  • Characterization of acute promyelocytic leukemia cases lacking the classic t (15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies"
    Grimwade, D; Biondi, A; Mozziconacci, MJ
  • Fusion between a novel Kruppellike zinc finger gene and the retinoic acid receptor-a locus due to avariant t (11;17) translocation associated with acute promyelocytic leukaemia
    Chen, Z; Brand, NJ; Chen, A
  • Fusion of retinoic acid receptor a to NuMA, the nuclear mitotic apparatus protein, by avariant translocation in acute promyelocytic leukaemia
    Wells, RA; Catzavelos, C; Kamel-Reid, S
  • The t (5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin retinoic acid receptor fusion
    Redner, RL; Rush, EA; Faas, S; Rudert, WA; Corey, SJ
  • The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor a in acute promyelocytic-like leukaemia
    Arnould, C; Philippe, C; Bourdon, V; Grgoire, MJ; Berger, R; Jonveaux, P
  • Understanding the molecular pathogenesis of acute promyelocytic leukaemia
    Lo-Coco, F; Hasan, SK
  • Acute promyelocytic leukemia: results of treatment by daunorubicin
    Bernard, J; Weil, M; Boiron, M
  • A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group
    Fenaux, P; Chastang, C; Chevret, S
  • Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
    Ades, L; Guerci, A; Raffoux, E
  • Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
    Lo-Coco, F; Avvisati, G; Vignetti, M
  • Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet
    Lengfelder, E; Lo-Coco, F; Ades, L
  • Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    Sanz, MA; Grimwade, D; Tallman, MS
  • RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t (11;17) acute promyelocytic leukemia
    Guidez, F; Parks, S; Wong, H
  • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    Lo-Coco, F; Avvisati, G; Vignetti, M
  • Treatment of acute promyelocytic leukaemia
    Fenaux, P; Chomienne, C; Degos, L
  • Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
    Lo-Coco, F; Diverio, D; Pandolfi, PP
  • Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program
    Beillard, E; Pallisgaard, N; Velden, VH
  • Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
    Mandelli, F; Diverio, D; Avvisati, G
  • A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia PETHEMA group
    Sanz, MA; Martin, G; Rayon, C
  • Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups
    Sanz, MA; Lo-Coco, F; Martín, G
  • Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RARa fusion mRNA
    Miller, WH; Levine, K; DeBlasio, A; Frankel, SR; Dmitrovsky, E; Warrell, RP
  • Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptasepolymerase chain reaction
    Huang, W; Sun, G-L; Li, X-S
  • Prognostic significance of the RT-PCR assay of PML/RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho)
    Fukutani, H; Naoe, T; Ohno, R
  • Absence of detectable PML/RARα fusion transcripts in long-term remission patients after bone marrow transplantation for acute promyelocytic leukemia
    Roman, J; Martin, C; Torres, A
  • Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial
    Burnett, AK; Grimwade, D; Solomon, E; Wheatley, K; Goldstone, AH
  • Early detection of relapse by prospective RT-PCR analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ‘‘AIDA’’ trial
    Diverio, D; Rossi, V; Avvisati, G
  • Therapy of molecular relapse in acute promyelocytic leukemia
    Lo-Coco, F; Diverio, D; Avvisati, G
  • Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention
    Esteve, J; Escoda, L; Martín, G
  • Minimal residual disease after allogenic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse
    Cross, NC; Hughes, TP; Feng, L
  • Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t (8;21) leukemia
    Jurlander, J; Caligiuri, MA; Ruutu, T
  • Prognostic significance of minimal residual disease detection and PML/RARa isoform type: long-term followup in acute promyelocytic leukemia
    Jurcic, JG; Nimer, SD; Scheinberg, DA
  • RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL
    Tobal, K; Liu, YJ
  • Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia
    Santamaria, C; Chillón, MC; Fernández, C
  • Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial
    Burnett, AK; Grimwade, D; Solomon, E
  • Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML
    Flora, R; Grimwade, D
  • Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
    Lo-Coco, F; Diverio, D; Falini, B
  • Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia
    Grimwade, D; Lo-Coco, F
  • United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial
    Burnett, AK; Hills, RK; Grimwade, D
  • Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy
    Grimwade, D; Jovanovic, JV; Hills, RK
  • Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
    Sanz, MA; Montesinos, P; Vellenga, E
  • Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group
    Sanz, MA; Martín, G; González, M
  • Acute promyelocytic leukemia: from highly fatal to highly curable
    Wang, ZY; Chen, Z
  • Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose dependent dual effects on APL cells
    Chen, GQ; Shi, XG; Tang, W
  • Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
    Ghavamzadeh, A; Alimoghaddam, K; Ghaffari, SH
  • Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia
    Ghavamzadeh, A; Alimoghaddam, K; Rostami, S
  • Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
    Mathews, V; George, B; Lakshmi, KM
  • Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data
    Mathews, V; George, B; Chendamarai, E
  • Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy
    Chendamarai, E; Balasubramanian, P; George, B
  • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north American Leukemia Intergroup Study C9710
    Powell, BL; Moser, B; Stock, W
  • Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Estey, E; Garcia-Manero, G; Ferrajoli, A
  • Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    Ravandi, F; Estey, E; Jones, D
  • Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients
    Shen, ZX; Chen, GQ; Ni, JH
  • Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
    Niu, C; Yan, H; Yu, T
  • Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia
    Au, WY; Lie, AK; Chim, CS
  • Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience
    Lazo, G; Kantarjian, H; Estey, E
  • Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia
    Raffoux, E; Rousselot, P; Poupon, J
  • All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
    Shen, ZX; Shi, ZZ; Fang, J
  • Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
    Lo-Coco, F; Cimino, G; Breccia, M
  • Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene
    Meloni, G; Diverio, D; Vignetti, M
  • Treatment of relapsed or refractory acute promyelocytic leukemia
    Tallman, MS
  • Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease
    Lo-Coco, F; Romano, A; Mengarelli, A
  • Hills RK Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
    Grimwade, D; Jovanovic, JV
  • Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
    Burnett, AK; Russell, NH; Hills, RK
  • Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
    Licht, JD; Chomienne, C; Goy, A
  • Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia
    Jovanovic, JV; Rennie, K; Culligan, D